ACU NUCLEAR SALT REACTOR: Tackling water & energy issues while advancing cancer treatment
ABILENE, Texas () – When most of us think of nuclear power, we often recall the negative aspects associated with this type of energy. However, Abilene Christian University is striving to change that perception with its molten salt research reactor. They are exploring research avenues such as water desalination, clean energy production, and cancer treatments, all in the hopes of advancing technology and medicine.
Earlier this week, Abilene Christian University revealed a partnership with Texas Tech University and Natura Resources to deploy Natura's molten salt reactor (MSR). The goal of this collaboration is to combine MSR technology with water desalination and energy production systems, tackling the energy and water challenges faced by Texas.
New project will use ACU salt reactor to 'address Texas' critical energy and water needs'
ACU's plans for the Natura MSR-1, a liquid-fueled molten salt reactor, began several years ago. In 2022, they initiated the application process to gain approval for a molten salt research reactor. Currently, the reactor is still under construction at ACU's NEXT Lab and will be used for experiments aimed at advancing technology and medicine.
Director of ACU's NEXT Lab, Dr. Rusty Towell, shared how this reactor can also produce clean water while producing electricity.
'If you have dirty water to clean it, just needs energy. You can, of course, boil it off,' Towell explained. 'We can actually use the waste heat from water reactors, the leftover heat that's normally just rejected to the air. We can use that to clean water. So while we produce electricity, we can also produce clean water.'
ACU conducts AI research: Exploring benefits, challenges with support from Google grant
While water purification is important, especially here in Texas with our water supplies, this lab also has another purpose: utilizing radioactive isotopes for medical research to fight cancer. Towell explained how radioisotopes produced by the reactor can be used to specifically target and rapidly eliminate cancer cells.
'Those radioisotopes are produced basically in the core of stars and the core of nuclear reactors, but they only last for a few hours or days, maybe,' Towell shared. 'So how do you get them from those locations where they're made in the doctor's hands? This technology will allow us to do that. We're working on producing the raw materials that doctors need for these new treatments.'
The research reactor is one of only two reactors of its kind in the nation.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.
Miami Herald
5 hours ago
- Miami Herald
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
9 hours ago
- Yahoo
Webb telescope spots infant planets in different stages of development
By Will Dunham WASHINGTON (Reuters) -The James Webb Space Telescope has observed two large planets at different stages of infancy - one with an atmosphere brimming with dusty clouds and the other encircled by a disk of material - orbiting a young sun-like star in a discovery that illustrates the complex nature of how planetary systems develop. The two gas giant planets, both more massive than our solar system's largest planet Jupiter, were directly imaged by Webb in a planetary system located in the Milky Way galaxy about 310 light years from Earth in the direction of the constellation Musca. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km). Astronomers have detected more than 5,900 planets beyond our solar system - called exoplanets - since the 1990s, with less than 2% of these directly imaged like these two. It is rare to find exoplanets in their early developmental stages. The birth of a planetary system begins with a large cloud of gas and dust - called a molecular cloud - that collapses under its own gravity to form a central star. Leftover material spinning around the star in what is called a protoplanetary disk forms planets. This planetary system was observed by Webb very early in its developmental history. The star, named YSES-1, is about the same mass as the sun. The two planets orbit a long distance from the star, each probably needing thousands of years to complete a single orbit. While the sun is roughly 4.5 billion years old, this star is approximately 16 million years old, a veritable newborn. The researchers were surprised to find that the two neonatal planets observed by Webb appeared to be at different stages of development. The innermost of the two has a mass about 14 times greater than Jupiter and orbits the star at a distance 160 times greater than Earth orbits the sun and more than five times as far as our solar system's outermost planet Neptune. The planet is surrounded by a disk of small-grained dust, a state one might expect in a very early stage of formation when it is still coalescing, or perhaps if there has been a collision of some kind or a moon is in the process of taking shape. Webb spotted water and carbon monoxide in its atmosphere. The outermost planet has a mass about six times greater than that of Jupiter and orbits the star at 320 times the distance of Earth to the sun. Its atmosphere is loaded with silicate clouds, differing from our solar system's gas giants. Webb also detected methane, water, carbon monoxide and carbon dioxide in the atmosphere. It has no disk of material around it. The puzzling combination of traits presented by these two planets in the same system illustrates "the complex landscape that is planet formation and shows how much we truly don't know about how planetary systems came to be, including our own," said astrophysicist Kielan Hoch of the Space Telescope Science Institute in Baltimore, who led the study published this week in the journal Nature. "Theoretically, the planets should be forming around the same time, as planet formation happens fairly quickly, within about one million years," Hoch said. A real mystery is the location where the planets formed, Hoch added, noting that their orbital distance from the host star is greater than would be expected if they formed in the protoplanetary disk. "Furthermore, why one planet still retains material around it and one has distinct silicate clouds remains a big question. Do we expect all giant planets to form the same way and look the same if they formed in the same environment? These are questions we have been investigating for ages to place the formation of our own solar system into context," Hoch said. In addition to amassing a trove of discoveries about the early universe since becoming operational in 2022, Webb has made a major contribution to the study of exoplanets with its observations at near- and mid-infrared wavelengths. "Webb is revealing all sorts of atmospheric physics and chemistry happening in exoplanets that we didn't know before, and is currently challenging every atmospheric model we used pre-Webb," Hoch said.
